Complementary mAb Polishing Solutions for Viral Clearance and Aggregate Removal - Register Now!
|Articles|April 15, 2002

BioPharm International

  • BioPharm International-09-01-2002
  • Volume 15
  • Issue 9

Virus Inactivation in the 1990s ? and into the 21st Century Part 3a, Plasma and Plasma Products (Heat and Solvent/Detergent Treatments)

Author(s)Gail Sofer

by Gail Sofer, BioReliance Plasma products have been associated with high levels of risk from viral contamination; therefore, most viral inactivation methods described in the literature during the past ten years have addressed plasma and plasma products. Plasma is the largest group to cover, and Part 3 takes two articles in our series to describe the many methods published. This article covers heat and solvent/detergent inactivation treatments for plasma.

Related to this article

The BioPharm Brief: Room Temperature, RNA, and ADCs
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.